Ginkgo Bioworks Holdings (DNA) EPS (Weighted Average and Diluted) (2020 - 2025)
Ginkgo Bioworks Holdings (DNA) reported EPS (Weighted Average and Diluted) of -$1.42 for Q4 2025, up 27.55% on a YoY basis from -$1.11 in Q4 2024, and up 2.07% quarter-over-quarter from -$1.45 in Q3 2025.
Ginkgo Bioworks Holdings (DNA) EPS (Weighted Average and Diluted) (2020 - 2025) Analysis & Trends
Ginkgo Bioworks Holdings has reported EPS (Weighted Average and Diluted) for 6 years, with the latest figure at -$1.42 in Q4 2025.
- For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) rose 27.55% year-over-year to -$1.42; the trailing twelve-month figure through Dec 2025 stood at -$5.65 (up 46.65% YoY), and the FY2025 full-year result was -$5.64, up 46.49% from the prior year.
- EPS (Weighted Average and Diluted) for Q4 2025 stood at -$1.42, up from -$1.45 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was -$0.04 in Q2 2021, with the low at -$49.01 in Q4 2022.
- Historically, EPS (Weighted Average and Diluted) has averaged -$4.13 across 5 years, with a median of -$1.21 in 2021.
- Annual changes were most pronounced in 2023 — EPS (Weighted Average and Diluted) soared 91.27% — and 2024, when it sank 4600.0%.
- Ginkgo Bioworks Holdings' EPS (Weighted Average and Diluted) stood at -$1.21 in 2021, then plunged by 3950.41% to -$49.01 in 2022, then soared by 91.27% to -$4.28 in 2023, then surged by 54.21% to -$1.96 in 2024, then advanced by 27.55% to -$1.42 in 2025.
- The last three EPS (Weighted Average and Diluted) figures came in at -$1.42 (Q4 2025), -$1.45 (Q3 2025), and -$1.1 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Ginkgo Bioworks Holdings | 546.79 Mn | 546.79 Mn | 16.38 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.42 |
| Sep 30, 2025 | -1.45 |
| Jun 30, 2025 | -1.10 |
| Mar 31, 2025 | -1.68 |
| Dec 31, 2024 | -1.96 |
| Sep 30, 2024 | -1.08 |
| Jun 30, 2024 | -4.23 |
| Mar 31, 2024 | -3.32 |
| Dec 31, 2023 | -4.28 |
| Sep 30, 2023 | -6.21 |
| Jun 30, 2023 | -0.09 |
| Mar 31, 2023 | -0.11 |
| Dec 31, 2022 | -49.01 |
| Sep 30, 2022 | -0.41 |
| Jun 30, 2022 | -0.41 |
| Mar 31, 2022 | -0.37 |
| Dec 31, 2021 | -1.21 |
| Sep 30, 2021 | -0.08 |
| Jun 30, 2021 | -0.04 |
| Dec 31, 2020 | -0.04 |